Researchers at the University of Pennsylvania have shown that lipid nanoparticles can mediate more than 100-fold greater mRNA delivery to the placenta of pregnant mice with pre-eclampsia than a lipid nanoparticle formulation approved by the U.S. Food and Drug Administration. These lipid nanoparticles can decrease high blood pressure and increase vasodilation in these pre-eclamptic pregnant mice.
These research results offer hope to develop a cure for pre-eclampsia in humans, a condition that arises due to insufficient blood flow to the placenta and results in high maternal blood pressure and restricted blood flow to the fetus.